Valuation: Telix Pharmaceuticals Limited

Market Cap 4.58B 3.22B 2.89B 2.66B 2.41B 4.51B 307B 31.78B 12.68B 161B 12.1B 11.84B 509B P/E 2026 *
203x
P/E 2027 * 2,399x
Enterprise Value 5.11B 3.6B 3.22B 2.97B 2.69B 5.03B 342B 35.45B 14.14B 179B 13.49B 13.21B 568B EV / Sales 2026 *
3.67x
EV / Sales 2027 * 3.22x
Free-Float
84.31%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Telix Pharmaceuticals Limited

1 day+3.22%
1 week-7.16%
Current month-14.25%
1 month-16.22%
3 months-6.84%
6 months-8.55%
Current year+20.36%
1 week 12.61
Extreme 12.61
13.86
1 month 12.61
Extreme 12.61
16.5
Current year 8.26
Extreme 8.26
18.22
1 year 8.26
Extreme 8.26
18.22
3 years 8.26
Extreme 8.26
31.97
5 years 3.55
Extreme 3.55
31.97
10 years 0.46
Extreme 0.46
31.97
Manager TitleAgeSince
Chief Executive Officer 51 03/01/2017
Director of Finance/CFO 61 31/07/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 51 03/01/2017
Chairman 66 03/02/2026
Director/Board Member 68 19/06/2018
Date Insider Type Main position Quantity % Market Cap. Importance
9/24/26 A Buy

Chairman

11,800 0.0035%
9/7/26 A Buy

Chief Financial Officer

2,071 0.0006%
5/26/26 A Free

Director

21,597 0.0064%
Change 5-day change 1-year change 3-year change Capi.($)
+3.22%-7.16%-17.95%+55.12% 3.12B
+0.34%-3.03%+37.45%+61.06% 64.14B
+0.98%+2.26%+12.91%+82.98% 55.53B
+1.75%+2.76%+12.38%+103.69% 53.03B
-1.43%-0.57%+26.10%+52.86% 45.99B
-0.48%-3.86%+17.27%+117.99% 42.45B
+0.82%-2.06%+227.09%+922.41% 40.45B
-0.26%-4.20%+10.86%+45.18% 32.25B
-2.07%+44.58%+102.84%+88.74% 34.47B
-2.72%-8.79%+22.58%-5.63% 24.23B
Average -0.01%+2.43%+45.15%+152.44% 39.57B
Weighted average by Cap. -0.09%+3.03%+48.73%+160.05%

Financials

2026 *2027 *
Net sales 1.39B 979M 877M 809M 732M 1.37B 93.24B 9.65B 3.85B 48.8B 3.67B 3.6B 155B 1.57B 1.11B 992M 915M 828M 1.55B 105B 10.92B 4.35B 55.18B 4.16B 4.07B 175B
Net income 27.02M 19.02M 17.03M 15.72M 14.22M 26.59M 1.81B 187M 74.8M 948M 71.37M 69.85M 3B 2.51M 1.76M 1.58M 1.46M 1.32M 2.47M 168M 17.39M 6.94M 87.92M 6.62M 6.48M 278M
Net Debt 529M 372M 333M 307M 278M 520M 35.43B 3.67B 1.46B 18.54B 1.4B 1.37B 58.73B 490M 345M 309M 285M 258M 482M 32.82B 3.4B 1.36B 17.18B 1.29B 1.27B 54.4B
Projected Income Statement - Annual - Telix Pharmaceuticals Limited
Logo Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Employees
1,152
Date Price Change Volume
29/10/26 A$13.48 +3.22% 1,803,720
28/10/26 A$13.06 +2.11% 4,042,702
27/10/26 A$12.79 -0.47% 2,945,488
26/10/26 A$12.85 -2.58% 4,418,896
23/10/26 A$13.19 -3.44% 3,151,131
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Telix Pharmaceuticals Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
13.48AUD
Average target price
24.17AUD
Spread / Average Target
+79.31%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Telix Pharmaceuticals Limited